Conditions: Relapsing-remitting Multiple Sclerosis
Keywords: Multiple Sclerosis FTY720 Fingolimod
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1272
Healthy volunteers: no

Brief summary:
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Fingolimod 1.25 mg intervention 2: Fingolimod 0.5 mg intervention 3: Placebo
Intervention descriptions: intervention 1: Patients self-administered fingolimod 1.25 mg capsules orally once daily. intervention 2: Patients self-administered fingolimod 0.5 mg capsules orally once daily. intervention 3: Patients self-administered a fingolimod placebo capsule orally once daily.

Protocol document: